About: Aurélien Marabelle

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Aurélien Marabelle Goto Sponge NotDistinct Permalink

An Entity of Type : foaf:Person, within Data Space : data.idref.fr associated with source document(s)

Attributes	Values
type	Person
sameAs	Marabelle, Aurélien (1976-....) Marabelle, Aurélien (1976-....) Marabelle, Aurélien (1976-....) Marabelle, Aurélien (1976-....)
Life Event	http://www.idref.fr/118685589/birth
preferred label	Marabelle, Aurélien (1976-....)
name	Aurélien Marabelle
dbpedia-owl:citizenship	http://sws.geonames.org/3017382/
Language	http://lexvo.org/id/iso639-3/fra
isni:identifierValid	0000000356644430
Given name	Aurélien
familyName	Marabelle
note	Titulaire du diplôme d'état de docteur en Médecine (Clermont-Ferrand 1, 2007) Praticien hospitalier en oncologie, professeur à l'université Paris Saclay en 2023
gender	male
ORCID iD	0000-0002-5816-3019
Scopus ID	25622307000
is sameAs of	Marabelle, Aurélien (1976-....) Marabelle, Aurélien (1976-....) Marabelle, Aurélien (1976-....) Marabelle, Aurélien (1976-....)
is Thesis advisor of	http://www.sudoc.fr/242533736/id http://www.sudoc.fr/240941284/id http://www.sudoc.fr/258617977/id http://www.sudoc.fr/260078069/id http://www.sudoc.fr/275011348/id http://www.sudoc.fr/26963570X/id
is Praeses of	http://www.sudoc.fr/230560636/id
is Author of	http://www.sudoc.fr/171794613/id http://www.sudoc.fr/118735233/id Immune responses during COVID-19 infection The immuno-oncological challenge of COVID-19 A tribute to the life and career of Holbrook Kohrt Targeting immune effector cells to promote antibody-induced cytotoxicity in cancer immunotherapy. Abstract 2466: Sequential tumor and immune targeted immunotherapy: Anti-tumor activity of antibody drug conjugate Trastuzumab Emtansine (T-DM1) with CD137 stimulation in HER-2+ breast cancer therapy Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade https://serval.unil.ch/notice/serval:BIB_86BBC6AFEB18#id Neuropilin-1 cooperates with PD-1 in CD8+ T cells predicting outcomes in melanoma patients treated with anti-PD1 Genomic Instability and Pro-Tumoral Inflammation are associated with Primary Resistance to Anti-PD1 + Anti-Angiogenesis in Malignant Pleural Mesothelioma In Vitro and In Vivo Comparison of Lymphocytes Transduced with a Human CD16 or with a Chimeric Antigen Receptor Reveals Potential Off-Target Interactions due to the IgG2 CH2-CH3 CAR-Spacer Overcoming therapeutic MAb resistance in agressive HER2 positive breast carcinomas by adoptive immunotherapy using optizimed effectors cells NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients (18)F-FDG PET and CT-scan Detect New Imaging Patterns of Response and Progression in Patients with Hodgkin Lymphoma Treated by Anti-PD1 Immune Checkpoint Inhibitor. Stromal lymphocyte infiltration is associated with tumour invasion depth but is not prognostic in high-grade T1 bladder cancer Detection of tumor ALK status in neuroblastoma patients using peripheral blood Immunodynamics of explanted human tumors for immuno-oncology Intratumoral immunotherapy: using the tumor as the remedy Targeting CD137 enhances the efficacy of cetuximab. T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors Better than RECIST and faster than iRECIST: defining the Immunotherapy Progression Decision score to better manage progressive tumors on immunotherapy Immunophenotyping of Stage III Melanoma Reveals Parameters Associated with Patient Prognosis Hyperprogression upon immunotherapy: A chance for (hyper-)progress Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced Solid Tumors Biomarkers associated with checkpoint inhibitors Holbrook Kohrt: In Memoriam (1977-2016) Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell–mediated antitumor immune response Renal toxicities associated with pembrolizumab Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials CAR-T cells and BiTEs in solid tumors: challenges and perspectives Predictors of responses to immune checkpoint blockade in advanced melanoma Organisational factors influencing early clinical trials enrollment: Gustave Roussy experience Determination of 17q gain in patients with neuroblastoma by analysis of circulating DNA. Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy? Hair Repigmentation With Anti-PD-1 and Anti-PD-L1 Immunotherapy: A Novel Hypothesis https://serval.unil.ch/notice/serval:BIB_BF300CC80761#id Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study Long-term side effects of radiotherapy for pediatric localized neuroblastoma Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop Microenvironment-Driven Shift of Cohesion/Detachment Balance within Tumors Induces a Switch toward Metastasis in Neuroblastoma Safety and efficacy of nivolumab, an anti-PD1 immunotherapy, in patients with advanced basal cell carcinoma, after failure or intolerance to sonic Hedgehog inhibitors: UNICANCER AcSé NIVOLUMAB trial Repurposing infectious disease vaccines for intratumoral immunotherapy Neurological complications induced by immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae BCG therapy downregulates HLA-I on malignant cells to subvert antitumor immune responses in bladder cancer https://serval.unil.ch/notice/serval:BIB_B2B6B96BFA13#id https://archive-ouverte.unige.ch/unige:157635#id https://serval.unil.ch/notice/serval:BIB_FA16AC950873#id
is primary topic of	http://www.idref.fr/118685589
is Editor of	http://www.sudoc.fr/221253726/id
is Opponent of	http://www.sudoc.fr/200210890/id http://www.sudoc.fr/19408504X/id http://www.sudoc.fr/22169983X/id http://www.sudoc.fr/245194819/id http://www.sudoc.fr/276707427/id http://www.sudoc.fr/280002939/id http://www.sudoc.fr/234026324/id http://www.sudoc.fr/280367813/id http://www.sudoc.fr/237787342/id
is Thesis referee of	http://www.sudoc.fr/260310298/id http://www.sudoc.fr/261516248/id http://www.sudoc.fr/263168530/id

Faceted Search & Find service v1.13.91 as of Aug 16 2018

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of May 14 2019, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (70 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software